To our knowledge, this is the first report of carpal tunnel syndrome following Xiaflex injection. It is unlikely that the collagenase mix itself led to carpal tunnel syndrome, as the injection was very distal to the carpal tunnel. We suspect the primary causative factor was the swelling, which is very common following Xiaflex injection.1,4 The patient may have had subclinical carpal tunnel syndrome and the swelling from the Xiaflex treatment pushed him to develop symptoms. Given the scenario, we have since raised the question of whether Dupuytren patients would benefit from carpal tunnel syndrome screening before Xiaflex injection. Electromyography/nerve conduction velocity studies may not be necessary, but a thorough history and physical examination are likely warranted. Even if asymptomatic, provocative maneuvers such as Phalen and Durkan tests may help identify patients at risk and appropriately direct treatment.
The authors have no financial interest to declare in relation to the content of this article.
Valeriy Shubinets, M.D.
Ines C. Lin, M.D.
Benjamin Chang, M.D.
1. Desai SS, Hentz VRThe treatment of Dupuytren disease. J Hand Surg Am. 2011;36:936–942.
2. Warwick D, Arandes-Renú JM, Pajardi G, Witthaut J, Hurst LCCollagenase Clostridium histolyticum
: Emerging practice patterns and treatment advances. J Plast Surg Hand Surg. 2016;50:251–261.
3. Eaton CEvidence-based medicine: Dupuytren contracture. Plast Reconstr Surg. 2014;133:1241–1251.
4. Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PPSafety and tolerability of collagenase Clostridium histolyticum
and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur Vol. 2015;40:141–149.
5. Gaston RG, Larsen SE, Pess GM, et alThe efficacy and safety of concurrent collagenase Clostridium histolyticum
injections for 2 Dupuytren contractures in the same hand: A prospective, multicenter study. J Hand Surg Am. 2015;40:1963–1971.
Viewpoints, pertaining to issues of general interest, are welcome, even if they are not related to items previously published. Viewpoints may present unique techniques, brief technology updates, technical notes, and so on. Viewpoints will be published on a space-available basis because they are typically less timesensitive than Letters and other types of articles. Please note the following criteria:
* Text—maximum of 500 words (not including references)
* References—maximum of five
* Authors—no more than five
* Figures/Tables—no more than two figures and/or one table
Authors will be listed in the order in which they appear in the submission. Viewpoints should be submitted electronically via PRS’ enkwell, at www.editorialmanager.com/prs/. We strongly encourage authors to submit figures in color.
We reserve the right to edit Viewpoints to meet requirements of space and format. Any financial interests relevant to the content must be disclosed. Submission of a Viewpoint constitutes permission for the American Society of Plastic Surgeons and its licensees and assignees to publish it in the Journal and in any other form or medium.
The views, opinions, and conclusions expressed in the Viewpoints represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.